SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.
| Insider | Role | Date | Transaction | Shares | Value |
|---|---|---|---|---|---|
| Kurzius Lawrence Erik | 10% Owner | 2026-08-10 | Option exercise | 205538 | $10.1M |
| Kurzius Lawrence Erik | 10% Owner | 2026-08-10 | Open-market sell | 205538 | $10.8M |
| Conway Michael Aaron | Director | 2026-07-23 | Open-market buy | 1100 | $55K |
| Foley Brendan M | Chairman, President & CEO, Director | 2026-07-22 | J | 5 | $264 |
| Foley Brendan M | Chairman, President & CEO, Director | 2026-07-20 | J | 11 | $566 |
| Foust Andrew | Chief Integration Officer | 2026-07-20 | J | 51 | $3K |
| Foust Andrew | Chief Integration Officer | 2026-07-20 | J | 3 | $162 |
| Piper Sarah | Chief Human Relations Officer | 2026-07-20 | J | 21 | $1K |
| Hoots Cindy L | Director | 2026-06-01 | Grant/award | 527 | $25K |
| BRAMMAN ANNE L | Director | 2026-04-28 | J | 24 | $1K |
| Foley Brendan M | Chairman, President & CEO | 2026-04-28 | J | 5 | $257 |
| Foley Brendan M | Chairman, President & CEO | 2026-04-28 | J | 288 | $15K |
| Foust Andrew | Chief Integration Officer | 2026-04-28 | J | 52 | $3K |
| Foust Andrew | Chief Integration Officer | 2026-04-28 | J | 3 | $164 |
| Piper Sarah | Chief Human Relations Officer | 2026-04-28 | J | 21 | $1K |
| Sheppard Valarie L | Director | 2026-04-28 | J | 3 | $170 |
| THOMAS TERRY S | Director | 2026-04-28 | J | 4 | $196 |
| Foley Brendan M | Chairman, President & CEO, Director | 2026-04-27 | J | 11 | $565 |
| Hattersley Gavin | Director | 2026-04-10 | Open-market buy | 2000 | $106K |
| Foust Andrew | President, Americas | 2026-03-15 | Option exercise | 533 | $0 |
Fiscal period ending 2025-11-30 versus 2024-11-30 — view filing on EDGAR →
Risk exposure broadened across four distinct themes — macro/tariff pressures, supply chain inputs, regulatory product requirements, and consumer litigation — with no offsetting easings. The most consequential near-term developments are tariff-driven cost headwinds already impacting operations and new FDA synthetic dye phase-out requirements that could force product reformulation. While no single change reaches existential severity, the concurrent worsening across macro, regulatory, and legal dimensions represents a meaningful step-up in the overall risk profile.
3 company-specific · 1 common-mode
Added soybean oil as significant raw material with active hedging derivatives; expanded mitigation to include "other streamlining initiatives"; added "global trade policies" as governmental risk factor.
Issues regarding procurement of raw materials may negatively impact us. Our purchases of raw materials are subject to fluctuations in market price and availability caused by inflationary pressures…
New specific regulatory risks disclosed: FDA phase-out of synthetic dyes and MAHA Commission recommendations on chronic disease. These represent concrete regulatory developments with potential business impact.
Risks Related to Our Global Business, Litigation, Laws and Regulations Laws and regulations could adversely affect our business. Food products are extensively regulated in most of the countries in…
New disclosure of specific litigation risk: consumer class actions related to privacy and data security. Escalates from generic legal claims to identified threat category.
Litigation, legal or administrative proceedings could have an adverse impact on our business and financial condition or damage our reputation. We are party to a variety of legal claims and…
New disclosure of tariff-driven cost pressures and supply chain uncertainty already impacting operations. Material macro risk with quantifiable business impact.
Changes in global trade policies have impacted and may continue to impact our financial condition or results of operations. Changes in global trade policies, including tariffs, have caused…
Anne Bramman, a Board member and Chair of the Audit Committee, has informed the Board of her intention to resign effective November 30, 2026, due to her appointment as Executive Vice President and Chief Financial Officer of Best Buy Co., Inc. The departure of an Audit Committee chair is material to investors as it affects governance and oversight structure. While a successor (Valarie Sheppard) has been identified, the loss of an experienced audit committee leader represents a material change in the registrant's governance.
View raw filing on EDGAR →McCormick issued a press release on June 25, 2026 reporting second quarter fiscal 2026 financial results, including net sales growth of 16.7%, operating income, and earnings per share metrics. The filing includes unaudited consolidated financial statements (income statement, balance sheet, and cash flow statement) for the six-month period ended May 31, 2026, which is the standard format for quarterly earnings disclosures under Item 2.02.
View raw filing on EDGAR →The filing discloses the appointment of Cindy Hoots to McCormick's Board of Directors effective June 1, 2026, with assignment to the Audit Committee. This is a clear board appointment of a qualified executive (recently retired Chief Digital Officer and CIO of AstraZeneca PLC, current Zoom board member), which is material to investors as it affects board composition and governance.
View raw filing on EDGAR →